Filament Health posts $5M loss in 2024, faces liquidity concerns

Green Market Report The clinical-stage natural psychedelic company showed progress in its drug development pipeline while dealing with a shrinking runway. Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) reported a net loss of $4.97 million for 2024 while the botanical psychedelic drug developer expanded its clinical trial programs and intellectual property portfolio.   https://www.greenmarketreport.com/filament-health-posts-5m-loss-in-2024-faces-liquidity-concerns/